Disease Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group study

PURPOSE: GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evalua...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Gynecol Oncol
Prif Awduron: Rose, Peter G., Java, James J., Morgan, Mark A., Secord, Angeles Alvarez, Kesterson, Joshua P., Stehman, Frederick B., Warshal, David P., Creasman, William T., Hanjani, Parviz, Morris, Robert T., Copeland, Larry J.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2016
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720165/
https://ncbi.nlm.nih.gov/pubmed/27692669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.09.005
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg